In this section
@article{Crone:2020:10.1038/s41467-020-18130-3,
author = {Crone, M and Priestman, M and Ciechonska, M and Jensen, K and Sharp, D and Anand, A and Randell, P and Storch, M and Freemont, P},
doi = {10.1038/s41467-020-18130-3},
journal = {Nature Communications},
pages = {1--11},
title = {A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics},
url = {http://dx.doi.org/10.1038/s41467-020-18130-3},
volume = {11},
year = {2020}
}
TY - JOUR
AB - The SARS-CoV-2 pandemic has shown how a rapid rise in demand for patient and community sample testing can quickly overwhelm testing capability globally. With most diagnostic infrastructure dependent on specialized instruments, their exclusive reagent supplies quickly become bottlenecks, creating an urgent need for approaches to boost testing capacity. We address this challenge by refocusing the London Biofoundry onto the development of alternative testing pipelines. Here, we present a reagent-agnostic automated SARS-CoV-2 testing platform that can be quickly deployed and scaled. Using an in-house-generated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well as two detection assays based on CRISPR-Cas13a and RT-loop-mediated isothermal amplification (RT-LAMP). In collaboration with an NHS diagnostic testing lab, we report the performance of the overall workflow and detection of SARS-CoV-2 in patient samples using RT-qPCR, CRISPR-Cas13a, and RT-LAMP. The validated RNA extraction and RT-qPCR platform has been installed in NHS diagnostic labs, increasing testing capacity by 1000 samples per day.
AU - Crone,M
AU - Priestman,M
AU - Ciechonska,M
AU - Jensen,K
AU - Sharp,D
AU - Anand,A
AU - Randell,P
AU - Storch,M
AU - Freemont,P
DO - 10.1038/s41467-020-18130-3
EP - 11
PY - 2020///
SN - 2041-1723
SP - 1
TI - A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
T2 - Nature Communications
UR - http://dx.doi.org/10.1038/s41467-020-18130-3
UR - https://www.nature.com/articles/s41467-020-18130-3
UR - http://hdl.handle.net/10044/1/81660
VL - 11
ER -
Established in 2017 by its principal funder the Medical Research Council, in partnership with Alzheimer's Society and Alzheimer’s Research UK, The UK Dementia Research Institute (UK DRI) is the UK’s leading biomedical research institute dedicated to neurodegenerative diseases.
